NCT07517497 The Course of Acute Respiratory Failure in Geriatric Patients With Hip Fracture Using Different Modes of a Vibroacoustic Device for the Lungs
| NCT ID | NCT07517497 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Astana Medical University |
| Condition | Vibration |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-03-01 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A medical professional trained in the procedure and use of the device will conduct the vibroacoustic therapy session. He will also take blood samples. In the control group, patients will undergo vibroacoustic pulmonary therapy in the "Pneumonia" mode, and in the control group, in the "Prevention" mode. Vibroacoustic pulmonary therapy will be conducted over a period of 5 days. A similar algorithm of actions is planned for both groups. VALT sessions will be conducted 4-6 times a day for 5 minutes in combination with treatment according to the protocol for the use of "Vibroacoustic Therapy" of the lungs of the Ministry of Health of the Republic of Kazakhstan. The device's emitters will be applied to the affected areas of the lungs. Since the device has long cords for the emitters and is portable, it is not difficult to change the patient's position and does not require their active participation, which is important for patients on ventilators and with limited mobility.
Eligibility Criteria
* respiratory failure; * hip fracture; * Injury Severity Score no higher than 8 points. Exclusion Criteria: * All contraindications for use of the device: * terminal condition of the patient; * shock; * paradoxical pathological breathing; * hypertensive crisis; * severe hypocoagulation with a risk of hematoma formation or bleeding in the projection of exposure; * severe hypercoagulation, risk of thrombus/embolus migration along the main vessels in the area of exposure; * acute cerebrovascular accident in the first 1-3 days; * brain edema; * presence of multiple purulent or burn wound surfaces in the area of exposure; * presence of unstable rib fractures; * pneumomediastinum and/or subcutaneous emphysema of the chest; * osteomyelitis of the ribs and/or thoracic spine; * spinal fracture without orthopedic fixation; * chest or abdominal trauma with bleeding; * Injury Severity Score greater than 8 points; * concomitant diseases in the stage of decompensation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07517497 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 85 Years, studying Vibration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07517497 currently recruiting?
Yes, NCT07517497 is actively recruiting participants. Contact the research team at asemabek9@gmail.com for enrollment information.
Where is the NCT07517497 trial being conducted?
This trial is being conducted at Astana, Kazakhstan.
Who is sponsoring the NCT07517497 clinical trial?
NCT07517497 is sponsored by Astana Medical University. The trial plans to enroll 60 participants.